{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:04:48Z","timestamp":1793912688453,"version":"4.8.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Heart failure (HF) is an emerging, global epidemic associated with substantial morbidity and mortality. In recent years, significant advancements have been made in the development of pharmacotherapies that provide mortality benefits in HF. Research into the pathophysiology of HF with reduced ejection fraction (HFrEF) has identified significant abnormalities in the critical nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) cascade. In HFrEF, there is reduced NO bioavailability, impaired sGC activity, and upregulation of phosphodiesterase activity, all causing a significant decrease in cGMP, impairing vasodilation and increasing cardiac fibrosis and hypertrophy. Vericiguat, an sGC stimulator, was developed to potentially harness the therapeutic efficacy of this pathway. In a major clinical trial, vericiguat use in patients with HFrEF on guideline-directed medical therapy and recent worsening of HF resulted in a significant decrease in the composite of death from cardiovascular causes or first hospitalization for HF compared with placebo. Current American Heart Association guidelines recommend that in selected high-risk patients with HFrEF and recent worsening of HF already on guideline-directed medical therapy, initiation of the oral sGC stimulator vericiguat may be considered to reduce HF hospitalization and cardiovascular death. However, while vericiguat represents a major accomplishment in capitalizing on the therapeutic potential of the NO-sGC-cGMP pathway, there remain significant challenges regarding the personalization of therapy and identification of the phenotype of the HFrEF population that most benefits from vericiguat therapy. Further research is currently underway to identify vericiguat\u2019s potential role in the treatment of chronic stable HFrEF without recent worsening of HF.<\/jats:p>","DOI":"10.1097\/crd.0000000000000963","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:01:06Z","timestamp":1750424466000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Vericiguat, a Soluble Guanylate Cyclase Stimulator Approved for Heart Failure Treatment"],"prefix":"10.1097","author":[{"given":"Mohammed","family":"Kallash","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, School of Medicine, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, School of Medicine, Valhalla, NY"},{"name":"Department of Medicine, Westchester Medical Center, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"R1-20250620","first-page":"388","article-title":"Vericiguat: the fifth harmony of heart failure with reduced ejection fraction.","volume":"10","author":"Falco","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"R2-20250620","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology.","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"R3-20250620","first-page":"S26","article-title":"Insights into foundational therapies for heart failure with reduced ejection fraction.","volume":"45","author":"McMurray","year":"2022","journal-title":"Clin Cardiol"},{"key":"R4-20250620","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.pharmthera.2009.02.009","article-title":"Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.","volume":"122","author":"Tsai","year":"2009","journal-title":"Pharmacol Ther"},{"key":"R5-20250620","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurheartj\/ehr304","article-title":"Nitric oxide synthases: regulation and function.","volume":"33","author":"F\u00f6rstermann","year":"2012","journal-title":"Eur Heart J"},{"key":"R6-20250620","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000338150","article-title":"Characterization of the role of nitric oxide and its clinical applications.","volume":"122","author":"Levine","year":"2012","journal-title":"Cardiology"},{"key":"R7-20250620","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.mvr.2018.03.012","article-title":"Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy?","volume":"119","author":"Yuyun","year":"2018","journal-title":"Microvasc Res"},{"key":"R8-20250620","doi-asserted-by":"crossref","first-page":"112894","DOI":"10.1016\/j.biopha.2022.112894","article-title":"Development of vericiguat: the first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).","volume":"149","author":"Xia","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"R9-20250620","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.abb.2018.12.013","article-title":"Phosphodiesterase expression in the normal and failing heart.","volume":"662","author":"Li","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"R10-20250620","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.3390\/ijms241612866","article-title":"New therapeutics for heart failure: focusing on cGMP signaling.","volume":"24","author":"Mangmool","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R11-20250620","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2165\/00002512-199608060-00007","article-title":"The role of nitric oxide in heart failure. Potential for pharmacological intervention.","volume":"8","author":"Macdonald","year":"1996","journal-title":"Drugs Aging"},{"key":"R12-20250620","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/cvr\/cvab240","article-title":"Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology.","volume":"118","author":"Petraina","year":"2022","journal-title":"Cardiovasc Res"},{"key":"R13-20250620","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1161\/CIRCULATIONAHA.108.800292","article-title":"Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure.","volume":"119","author":"Lapp","year":"2009","journal-title":"Circulation"},{"key":"R14-20250620","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur Heart J"},{"key":"R15-20250620","doi-asserted-by":"crossref","first-page":"e021094","DOI":"10.1161\/JAHA.121.021094","article-title":"Blood pressure and safety events with vericiguat in the VICTORIA trial.","volume":"10","author":"Lam","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R16-20250620","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial.","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"R17-20250620","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction.","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"R18-20250620","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-Terminal Pro-B-Type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study.","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R19-20250620","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ejhf.3501","article-title":"Vericiguat global study in participants with chronic heart failure: design of the VICTOR trial.","volume":"27","author":"Reddy","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"R20-20250620","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"R21-20250620","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40273-021-01091-w","article-title":"Cost effectiveness of vericiguat for the treatment of chronic heart failure with reduced ejection fraction following a worsening heart failure event from a US medicare perspective.","volume":"39","author":"Alsumali","year":"2021","journal-title":"PharmacoEcon"},{"key":"R22-20250620","doi-asserted-by":"crossref","first-page":"e13624","DOI":"10.1111\/eci.13624","article-title":"Recent advances in pharmacological treatment of heart failure.","volume":"51","author":"Iacoviello","year":"2021","journal-title":"Eur J Clin Invest"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000963","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T13:01:09Z","timestamp":1750424469000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":22,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000963","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]}}}